Squamous cell carcinoma - Carcinoma Celloedd Squamous
☆ Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
Squamous cell carcinoma well differentiated ― Gwelir keratosis actinig cyfagos.
References
Squamous cell carcinoma (SCC) yw'r ail ganser y croen mwyaf cyffredin yn yr Unol Daleithiau, ar ôl basal cell carcinoma. Mae fel arfer yn dechrau o friwiau cyn-ganseraidd o'r enw actinic keratosis , a gall ledaenu i rannau eraill o'r corff. Y prif achos yw amlygiad i ymbelydredd uwchfioled (UV) o'r haul, sy'n cronni dros amser. Mae triniaeth fel arfer yn cynnwys tynnu llawfeddygol, yn enwedig ar gyfer SCC ar y pen a'r gwddf. Mae therapi ymbelydredd yn opsiwn i gleifion hŷn neu'r rhai na allant gael llawdriniaeth. Mae ataliad imiwnedd yn cynyddu'r risg o SCC. Er ei fod yn brin, gall SCC ledaenu, yn enwedig mewn cleifion â systemau imiwnedd gwan. Mae archwiliadau rheolaidd ac amddiffyniad rhag yr haul yn bwysig i'r rhai sydd â SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) yw'r ail ganser mwyaf cyffredin mewn pobl, ac mae ei niferoedd yn cynyddu. Er bod CSCC fel arfer yn dangos ymddygiad clinigol anfalaen, gall ledaenu'n lleol ac i rannau eraill o'r corff. Mae gwyddonwyr wedi nodi llwybrau penodol sy'n ymwneud â datblygu CSCC, gan arwain at driniaethau newydd. Mae'r nifer uchel o fwtaniadau a'r risg gynyddol mewn cleifion â gwrthimiwnedd wedi ysgogi datblygiad imiwnotherapi. Mae'r adolygiad hwn yn edrych ar wreiddiau genetig CSCC a'r triniaethau diweddaraf sy'n targedu moleciwlau penodol a'r system imiwnedd.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnosis a Thriniaeth
#Dermoscopy
#Skin biopsy